Development of new drugs for treatment of disease is an expensive, time-consuming and labour-intensive effort for both pharmaceutical companies and academics. For the past 15 years, "cost per approval" of ...
Oct 28, 2014
1.7 / 5 (3) | 0
As the Ebola crisis in Africa continues and concern ramps up in the United States, a pharmaceutical company with a Corvallis connection is ready to respond with a limited amount of a potentially promising new drug.
Nov 11, 2014
not rated yet | 0